Product Description
Mechanisms of Action: 5-HT2C Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Schizophrenia
Phase 1: Healthy Volunteers|Schizophrenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
3153B3-1128 | P1 |
Completed |
Healthy Volunteers |
2009-09-01 |
|
3153B1-2208 | P2 |
Withdrawn |
Schizophrenia |
2009-07-01 |
|
3153A1-2203 | P2 |
Completed |
Schizophrenia |
2008-06-01 |
|
3153A1-103 | P1 |
Completed |
Schizophrenia |
2006-08-01 |